secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001129928-26-000004
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics gets FDA Fast Track for pelareorep in 2L KRAS-mutant MSS mCRC; interim data expected YE 2026
--------------------------------------------------------------------------------

- FDA Fast Track Designation for pelareorep + bevacizumab + FOLFIRI in second-line KRAS-mutant MSS metastatic colorectal cancer.
- Clinical data showed 33% ORR (vs ~10% SOC), 16.6-month PFS (vs 5.7 mo SOC), 27-month OS (vs 11.2 mo SOC).
- Company plans controlled study with first site activated March 2026; interim data expected by end of 2026.
- Estimated addressable market $3-5 billion annually for this difficult-to-treat population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000004/0001129928-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000004/oncy-20260204.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer